Establishment and characterization of patient-derived cancer models of malignant peripheral nerve sheath tumors

被引:11
|
作者
Oyama, Rieko [1 ]
Kito, Fusako [1 ]
Takahashi, Mami [2 ]
Hattori, Emi [3 ]
Noguchi, Rei [3 ]
Takai, Yoko [1 ]
Sakumoto, Marimu [1 ]
Qiao, Zhiwei [3 ]
Toki, Shunichi [4 ]
Sugawara, Masato [4 ]
Tanzawa, Yoshikazu [4 ]
Kobayashi, Eisuke [4 ]
Nakatani, Fumihiko [4 ]
Iwata, Shintaro [4 ]
Yoshida, Akihiko [5 ,6 ]
Kawai, Akira [4 ]
Kondo, Tadashi [1 ,3 ]
机构
[1] Natl Canc Ctr, Res Inst, Dept Innovat Seeds Evaluat, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Res Inst, Cent Anim Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[3] Natl Canc Ctr, Res Inst, Div Rare Canc Res, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[4] Natl Canc Ctr, Div Musculoskeletal Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[5] Natl Canc Ctr, Dept Pathol, Chuo Ku, Tokyo 1040045, Japan
[6] Natl Canc Ctr, Clin Labs, Chuo Ku, Tokyo 1040045, Japan
关键词
Malignant peripheral nerve sheath tumor; Xenograft; Primary culture; Drug screening; PHASE-II; SOMATIC MUTATIONS; READ ALIGNMENT; TRANSFORMATION; SUZ12; PRC2;
D O I
10.1186/s12935-020-1128-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Malignant peripheral nerve sheath tumors (MPNSTs) are a rare subtype of soft-tissue sarcoma, derived from a peripheral branch or the sheath of the sciatic nerve, brachial plexus, or sacral plexus. The clinical outcomes for MPNST patients with unresectable or metastatic tumors are dismal, and novel therapeutic strategies are required. Although patient-derived cancer cell lines are vital for basic research and preclinical studies, few MPNST cell lines are available from public cell banks. Therefore, the aim of this study was to establish cancer cell lines derived from MPNST patients. Methods We used tumor tissues from five patients with MPNSTs, including one derived from a rare bone tissue MPNST. The tumor tissues were obtained at the time of surgery and were immediately processed to establish cell lines. A patient-derived xenograft was also established when a sufficient amount of tumor tissue was available. The characterization of established cells was performed with respect to cell proliferation, spheroid formation, and invasion. The mutation status of actionable genes was monitored by NCC Oncopanel, by which the mutation of 114 genes was assessed by next-generation sequencing. The response to anti-cancer agents, including anti-cancer drugs approved for the treatment of other malignancies was investigated in the established cell lines. Results We established five cell lines (NCC-MPNST1-C1, NCC-MPNST2-C1, NCC-MPNST3-C1, NCC-MPNST4-C1, and NCC-MPNST5-C1) from the original tumors, and also established patient-derived xenografts (PDXs) from which one cell line (NCC-MPNST3-X2-C1) was produced. The established MPNST cell lines proliferated continuously and formed spheroids while exhibiting distinct invasion abilities. The cell lines had typical mutations in the actionable genes, and the mutation profiles differed among the cell lines. The responsiveness to examined anti-cancer agents differed among cell lines; while the presence of an actionable gene mutation did not correspond with the response to the anticipated anti-cancer agents. Conclusion The established cell lines exhibit various characteristics, including proliferation and invasion potential. In addition, they had different mutation profiles and response to the anti-cancer agents. These observations suggest that the established cell lines will be useful for future research on MPNSTs.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] MALIGNANT PERIPHERAL-NERVE SHEATH TUMORS IN CHILDHOOD
    DUCATMAN, BS
    SCHEITHAUER, BW
    PIEPGRAS, DG
    REIMAN, HM
    JOURNAL OF NEURO-ONCOLOGY, 1984, 2 (03) : 241 - 248
  • [42] Systemic Options for Malignant Peripheral Nerve Sheath Tumors
    Ayesha Hassan
    Roberto Carmagnani Pestana
    Amanda Parkes
    Current Treatment Options in Oncology, 2021, 22
  • [43] Therapeutic targets for malignant peripheral nerve sheath tumors
    Wu, Lai Man Natalie
    Lu, Qing Richard
    FUTURE NEUROLOGY, 2019, 14 (01)
  • [44] Malignant peripheral nerve sheath tumors: A case report
    Serrano Marcal, N.
    Teixeira, E.
    Sotto-Mayor, R.
    Manique, A.
    Campos, P.
    Cruz, J.
    Mendes de Almeida, M.
    Bugalho de Almeida, A.
    REVISTA PORTUGUESA DE PNEUMOLOGIA, 2010, 16 (03) : 483 - 492
  • [45] Honokiol: Treatment for malignant peripheral nerve sheath tumors
    Joshi, Megha Rajeev
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (05) : 1485 - 1486
  • [46] MALIGNANT PERIPHERAL-NERVE SHEATH TUMORS OF THE SKIN
    WICK, MR
    MAYO CLINIC PROCEEDINGS, 1990, 65 (02) : 279 - 282
  • [47] PRAME expression in malignant peripheral nerve sheath tumors
    Cadwell, Cathryn
    Yuksek, Gul
    Pekmezci, Melike
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2020, 79 (06): : 714 - 714
  • [48] ORBITAL MALIGNANT PERIPHERAL-NERVE SHEATH TUMORS
    LYONS, CJ
    MCNAB, AA
    GARNER, A
    WRIGHT, JE
    BRITISH JOURNAL OF OPHTHALMOLOGY, 1989, 73 (09) : 731 - 738
  • [49] MALIGNANT PERIPHERAL-NERVE SHEATH TUMORS OF THE SKIN
    GEORGE, E
    SWANSON, PE
    WICK, MR
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 1989, 11 (03) : 213 - 221
  • [50] Deregulated microRNAs in neurofibromatosis type 1 derived malignant peripheral nerve sheath tumors
    Amirnasr, Azadeh
    Verdijk, Robert M.
    van Kuijk, Patricia F.
    Kartal, Pinar
    Vriends, Anne L. M.
    French, Pim J.
    van Royen, Martin E.
    Taal, Walter
    Sleijfer, Stefan
    Wiemer, Erik A. C.
    SCIENTIFIC REPORTS, 2020, 10 (01)